Neurocrine Biosciences, Inc.

Valuation Analysis

About the Company

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's dise

Neurocrine Biosciences, Inc. Stock at a Glance

Neurocrine Biosciences, Inc. (NBIX) is currently trading at $159.76 with a market capitalization of $16.1B. The trailing P/E ratio stands at 24.58x, with a forward P/E of 12.57x. The 52-week range spans from $122.14 to $169.57; the current price is 5.8% below the yearly high. Year-over-year revenue growth stands at +42.2%. The net profit margin stands at 21.55%.

💰 Dividend

Neurocrine Biosciences, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

29 analysts rate Neurocrine Biosciences, Inc. (NBIX) on consensus: Strong Buy. The average price target is $192.88, implying +20.73% from the current price. Analyst price targets range from $144.00 to $250.65.

Neurocrine Biosciences, Inc.: The Investment Case in Detail

Neurocrine Biosciences, Inc. (NBIX) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Top-line momentum is unusually strong with revenue expanding 42.2% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 64.37%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 21.55%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Valuation in Context

With a PEG ratio of 0.45, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

What to Watch Next

• The forward P/E of 12.57x is meaningfully below the trailing 24.58x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 20.73% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (7.16%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Neurocrine Biosciences, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.